"Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia" by David S. Krause

Article

Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia

Antimicrobial Agents and Chemotherapy (2004)

David S. Krause, Delta Air Lines
John Reinhardt, Christiana Care Health System
Jose A. Vazquez, Wayne State University
Annette Reboli, University of Medicine and Dentistry of New Jersey
Beth P. Goldstein, Pfizer
Michele Wible
Timothy Henkel, Pfizer

Link

Disciplines

Medicine and Health Sciences and
Critical Care

Publication Date

June 1, 2004

DOI

10.1128/AAC.48.6.2021-2024.2004

Citation Information

David S. Krause, John Reinhardt, Jose A. Vazquez, Annette Reboli, et al.. "Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia" Antimicrobial Agents and Chemotherapy Vol. 48 Iss. 6 (2004) p. 2021 - 2024
Available at: http://works.bepress.com/annette-reboli/43/